logo    Company Page

Changed Risks for HAEMONETICS CORP (HAE)

Here are risks that changed year over year. risks from the recent filings of HAEMONETICS CORP. Our algorithms work hard to highlight risks unique to this company.
We outsource certain aspects of our business to a single third-party vendor that subjects us to risks, including disruptions in business and increased costs
If our business strategy does not yield the expected results or we fail to implement the necessary changes to our operations, we could see material adverse effects on our business, financial condition or results of operations
Earnings Per Share,
We sell our products in certain emerging economies which exposes us to less mature regulatory systems, more volatile markets for our products and greater credit risks A loss of funding for our products or changes to the regulatory regime could lead to lost revenue or account receivables  
If we are unable to successfully launch our NexSys PCS plasmapheresis system, our business may be materially and adversely affected
We are subject to the risks associated with communicable diseases A significant outbreak of a disease could reduce the demand for our products and affect our ability to provide our customers with products and services  
We recorded goodwill and other asset impairment charges that reduced our income during fiscal 2017 and may record additional charges in future periods
Our products may be determined to infringe another party's patent, which could lead to financial losses or adversely affect our ability to market our products  
We are increasingly dependent on information technology systems and subject to privacy and security laws and a cyber-attack or other breach of these systems could have a material adverse effect on our business, financial condition or results of operations
There is a risk that our intellectual property may be subject to misappropriation in some countries  
Many of our competitors have significantly greater financial means and resources, which may allow them to more rapidly develop new technologies and more quickly address changes in customer requirements  
Plastics are the principal component of our disposables, which are the main source of our revenues Any change in the price, composition or availability of the plastics we purchase could adversely affect our business
We may not realize the benefits we expect from our Complexity Reduction Initiative
A recall of our products, either voluntarily or at the direction of the FDA, another governmental authority, or a foreign competent authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on us
Our share repurchase program could affect the price of our common stock and increase volatility and may be suspended or terminated at any time, which may result in a decrease in the trading price of our common stock
Our relationships with customers and third-party payors are subject to applicable anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion, contractual damages, reputational harm and diminished profits and future earnings
If we or our suppliers fail to comply with ongoing regulatory requirements, our products could be subject to restrictions or withdrawal from the market
Quality problems with our processes, goods and services could harm our reputation for producing high-quality products and erode our competitive advantage, sales and market share
As a medical device manufacturer we are subject to a number of laws and regulations Non-compliance with those laws or regulations could adversely affect our financial condition and results of operations  
If we are unable to successfully expand our product lines through internal research and development and acquisitions, our business may be materially and adversely affected  
If we are unable to successfully grow our business through business relationships and acquisitions, our business may be materially and adversely affected  
We operate in an industry susceptible to significant product liability claims Product liability claims could damage our reputation and impair our ability to market our products or obtain professional or product liability insurance, or increase the cost of such insurance
We have a complex global supply chain Disruptions to this system could delay our ability to deliver finished products  
We are exposed to fluctuations in currency exchange rates, which could adversely affect our cash flows and results of operations 
As a substantial amount of our revenue comes from outside the US, we are subject to geopolitical events, economic volatility, violations of anti-corruption laws, export and import restrictions and tariffs, decisions by local regulatory authorities and the laws and medical practices in foreign jurisdictions  

Debug Info- Version: 2.4